Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

CD370 (Clec9A) Mouse anti-Human, PE, Clone: 9A11, eBioscience™ Non-distribution product as customer accommodation.

Mouse Monoclonal Antibody

Manufacturer:  Invitrogen 12370942

 View more versions of this product

Catalog No. 12370942

Add to cart



This monoclonal antibody 9A11 reacts with human CD370, also known as C-type lectin family member 9A (Clec9A) and DNGR1. This type II transmembrane glycoprotein is present at the cell surface in the form of a homodimer. CD370 is a cellular receptor expressed by myeloid cells that recognizes F-actin, a dead cell-associated antigen that is exposed in necrotic cells. Upon ligation, CD370 recruits Syk kinase to the ITAM-like motif in its intracellular tail and facilitates endocytosis of antigenic material that is subsequently processed and cross-presented to CD8+ T cells. Human CD370 is expressed by CD141+ (BDCA3+) dendritic cells and, to a lesser degree, by CD14+ CD16- monocytes. Unlike in mice, human plasmacytoid dendritic cells do not express CD370. This 9A11 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Filtration: 0.2 μm post-manufacturing filtered.

CLEC9A is a group V CTLR (C-type lectin-like receptor) that functions as an activation receptor and is expressed on myeloid lineage cells. This protein is also expressed at the cell surface and acts as glycosylated dimers which mediate endocytosis, but not phagocytosis (Poulin LF et al, 2010). It facilitates antigen uptake and presentation, and may provide a suitable target for antibody-mediated antigen delivery. CLEC9A is important for conveying information from necrotic cells to T-cells and defines a pathway by which adaptive immune responses can be initiated in the absence of infection. It recruits Syk to mediate sensing of necrosis by the principal DC subset involved in regulating cross priming to cell-associated antigens. Signaling via this kinase occurs through a novel pathway involving CARD9 which induce a variety of cellular responses including the induction of cytokines (such as TNF, IL-6, IL-10, IL-23, and IL-2), the respiratory burst, and the production of Arachidonic acid. In addition, it also induces TH17 (T-helper type 17) adaptive responses in vivo. Expression of CLEC9A is highly restricted in peripheral blood, being detected only on BDCA3+ DCs and on a small subset of CD14+ CD16- monocytes. CLEC9A serves as a new marker to distinguish subtypes of DCs.


CD370 (Clec9A)
5 μL/Test
PBS with 0.1% gelatin, 0.2% BSA and 0.09% sodium azide
Affinity chromatography
Flow Cytometry
IgG1, kappa
100 Tests
4° C, store in dark, DO NOT FREEZE!
Provide Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit

For Research Use Only